Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
18
Participants
Timeline
Start Date
July 31, 2014
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Conditions
Human Volunteer
Interventions
DRUG
OPRX-106
Trial Locations (1)
Unknown
Hadassah Medical Organization, Jerusalem
All Listed Sponsors
lead
Protalix
INDUSTRY
NCT02107833 - Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers | Biotech Hunter | Biotech Hunter